Rationale to Treat Alzheimer’s Disease with Selegiline — Can We Prevent the Progression of the Disease?
Alzheimer’s disease (AD) is a major cause of dementing illness in the developed countries and accounts for a disproportionate share of medical resource utilization and health care expenditures (Hay and Ernst, 1987). Unless an effective treatment regime or preventive measures are found for AD, the magnitude of the problem will continue to increase.
KeywordsClinical Global Impression Brief Psychiatric Rate Scale Trail Make Test Verbal Fluency Test Parkinson Study Group
Unable to display preview. Download preview PDF.
- Heinonen EH, Haapalinna A, Suhonen J and Hervonen A (1995): Selegiline may slow down age-related cognitive deterioration. Eur J Neurol 2 (suppl. 1): 130.Google Scholar
- Mhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM (1984): Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Task Force on Alzheimer’s disease. Neurology 34:939–944.Google Scholar
- Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, van Belle G, Fillenbaum G and Heyman A (1993): The Consortium to establish a registry for Alzheimer’s disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessments of probable Alzheimer’s disease. Neurology 43:2457–2465.PubMedGoogle Scholar
- Reinikainen KJ (1994): Rationale for the use of selegiline in the treatment of Alzheimer’s disease. Neurobiol Aging 15:s66.Google Scholar